Study of DS-8201a in HER2-Low, Unresectable and/or Metastatic Breast Cancer

Mammella HER2+: gli antibody drug conjugateПодробнее

Dr. Iwata Discusses DS-8201a in HER2+ Breast CancerПодробнее

DS-8201 Safety Profile, Activity in HER2-expressing Breast CancerПодробнее

DS-8201 + pembro in patients HER2+ breast and NSCLCПодробнее

Study of Targeted Therapy for HER2-Positive Metastatic Breast CancerПодробнее

Clinical outcomes in women with metastatic HER2-low breast cancer in the real worldПодробнее

T-DXd; DS-8201a in subjects with HER2-positive metastatic breast cancer previously treated with ...Подробнее

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBCПодробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysisПодробнее

Overview of the management of HER2-low breast cancer patientsПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Remaining questions on the management of HER2-low breast cancerПодробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

Study of Immunotherapy Combinations for Patients with HER2-Positive Metastatic Breast CancerПодробнее

Is HER2-low a distinct subtype of breast cancer?Подробнее

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer ParadigmПодробнее

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markersПодробнее